Literature DB >> 3677093

Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.

W R Waud1.   

Abstract

The uptake of cis-[14C]dichloro(ethylenediamine)platinum(II) (cis-DEP) is reduced in cis-diamminedichloroplatinum(II) (cis-DDP)-resistant L1210 cells [L1210/DDP (SRI)] in comparison to cis-DDP-sensitive L1210 cells (L1210/0). A difference in uptake is observed as early as 6 min after addition of cis-[14C]DEP and increases to approximately 3-fold after 30 min. This reduction in uptake is reflected in a decrease in the binding of platinum to DNA isolated from cis-DDP-treated cells as measured by atomic absorption spectroscopy and in the quantity of intracellular cis-DEP metabolites as measured by high-performance liquid chromatography. Similar differences in uptake are observed between ascitic L1210/0 and L1210/DDP (SRI) cells in vitro and in vivo, showing that the differences in uptake are not due to an artifact of the culturing process. The differences in cis-DEP uptake between the two cell lines were relatively unchanged during 7 mo in culture; however, both cell lines exhibited altered sensitivities to cis-DEP during extended culturing. No difference was observed in the efflux of cis-DEP by the two cell lines. Similarly, no difference in nonprotein and total sulfhydryl contents was observed between L1210/0 and L1210/DDP (SRI) cells. The difference in uptake (3-fold) of cis-DEP between L1210/0 and L1210/DDP (SRI) cells may not account fully for the observed differences in sensitivity of the two cell lines to cis-DDP (18-fold) and cis-DEP (19-fold). A portion of the resistance may be due to differences in the capacity of the two cell lines to survive in the presence of platinum damage.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3677093

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum.

Authors:  K Ikeda; K Miura; S Himeno; N Imura; A Naganuma
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

Review 2.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.

Authors:  R D Christen; D K Hom; D C Porter; P A Andrews; C L MacLeod; L Hafstrom; S B Howell
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

4.  Identification of semaphorin E as a non-MDR drug resistance gene of human cancers.

Authors:  T Yamada; R Endo; M Gotoh; S Hirohashi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

5.  Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.

Authors:  Brian G Blair; Christopher A Larson; Preston L Adams; Paolo B Abada; Catherine E Pesce; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2010-10-07       Impact factor: 4.436

6.  Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.

Authors:  W R Waud; S D Harrison; K S Gilbert; W R Laster; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

Authors:  S C Mann; P A Andrews; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 8.  Signaling and drug sensitivity.

Authors:  R D Christen; S Isonishi; J A Jones; A P Jekunen; D K Hom; R Kröning; D P Gately; F B Thiebaut; G Los; S B Howell
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

9.  Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.

Authors:  Brian G Blair; Christopher A Larson; Roohangiz Safaei; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

10.  Transient cisplatin-resistant murine fibrosarcoma cell characterized by increased metallothionein content.

Authors:  H Eichholtz-Wirth; R Born; G Reidel; B Hietel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.